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Table 3
Acute GVHD Characteristics
Variables Categories Bu-Cy Cy-Bu P
Acute GVHD Cumulative
incidence
3/18 (16.67%) 5/22(22.73%) .709
Median day
of onset
18 d (15-95) 28 d (16-55)
Mean  SD 39.75  37.48 33.12  15.90 .667
Grade of
acute GVHD
Grade 1 0 3 .236
Grade 2-4 4 4
Skin Stage 1 3 4 1.000
Stage 2-4 1 2
Liver Stage 1 1 0 .400
Stage 2-4 1 3
Gut Stage 1 0 0 1.000
Stage 2-4 2 2
Mortality Cumulative
incidence
1 (25%) 2 (28.57%) 1.000
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incidence, grade or stage of organ involved between the 2
groups.
Conclusion: As in previous studies hepatotoxicity in the
present analysis was found to be less in patients who
received Cy-Bu as the conditioning regimen and there was
earlier platelet engraftment in this group. These ﬁndings
suggest Cy-Bu has better toxicity proﬁle than conventional
Bu-Cy regimen. However further prospective studies are
required to conﬁrm these ﬁndings.Figure 1386
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The Anthony Nolan volunteer hematopoietic stem cell (HSC)
donor registry recently encountered two episodes of hema-
turia following the use of granulocyte colony stimulating
factor (G-CSF), highlighting how serious underlying medical
conditions may go unnoticed despite rigorous assessment.
A 28-year-old Caucasian male donor had an unremarkable
medical history at work-up. He reported an episode of self-
limiting frank hematuria one year previously. At that time, he
was diagnosed with an episode of possible haemorrhagic
cystitis. At the pre-donation assessment his creatinine was.
Haplo
HSCT
MRD
HSCT
UD
HSCT
N 31 47 63
Age: Median (range) 61 (55-73) 62 (55-71) 64 (57-71)
HCT-comorbidity Index > 2 62% 47% 47%
Myeloid Malignancies 49% 47% 54%
High/Very high disease
Risk index (DRI)
35% 35% 27%
Graft Failure 1 0 0
100 days 3-4 aGVHD 10% 15% 25%
1 Year severe cGVHD 0% 15% 15%
Overall NRM 10% 11% 37%
Overall relapse 19% 29% 25%
PFS 62% 61% 42%
PFS w/o cGVHD 62% 61% 35%
Figure.
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registry screening policy. He was declared medically ﬁt to
donate by G-CSF mobilized PBSC harvest, and commenced a
4-day course of recombinant glycosylated G-CSF at 10mg/kg
daily.
Shortly after administration of the third dose, he developed
frank hematuria. The fourth dose was omitted and PBSC
harvest occurred the following day. On the day of collection,
his creatinine had increased to 148 umol/l and quantitative
urinalysis showed frank hematuria and heavy proteinuria
(4.1g/day). He was reviewed by a nephrologist and a pre-
sumptive diagnosis of IgA nephropathy (IgAN) was made.
Renal biopsy features conﬁrmed this. Biochemical indices
resolved although proteinuria and microscopic hematuria
persisted ﬁve months later.
We encountered a similar case more recently, where a
28-year-old Caucasian male donor with an unremark-
able medical history developed hematuria after 3 doses
of G-CSF. A fourth dose was nevertheless administered
as the symptoms were not reported at the time. On
the day of collection, his creatinine was 77 umol/l and
urinalysis showed heavy hematuria but no proteinuria.
Five days post donation his renal imaging was normal
but quantitative urinalysis revealed heavy proteinuria
(5g/day). He was reviewed by a nephrologist two
weeks later and his proteinuria had improved to
approximately 0.5g/day. A presumptive diagnosis of
IgAN was suggested but a renal biopsy was not
deemed necessary given the improvement of his lab-
oratory indices.
In summary, these cases illustrate a proven and prob-
able pre-existing IgAN exacerbated by G-CSF. IgAN is a
common form of glomerulonephritis seen worldwide.
The use of G-CSF has previously been linked to he-
maturia and 2 case reports of proven IgAN have been
reported to date. The Serious Events and Adverse Re-
actions database held by the World Marrow Donor
Association (WMDA) reports 1 episode of unexplained
hematuria in G-CSF mobilized donors. This is likely an
underestimate particularly when cases present only
with asymptomatic proteinuria or microscopic hematu-
ria. We would urge all donor registries to report any
cases to the WMDA. We would also recommend the
introduction of urinalysis as part of the medical work-
up in all HSC donors and the follow-up management as
shown in Figure 1.Figure.387
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